96 related articles for article (PubMed ID: 21261708)
1. Much ado about Nutlin.
Teoh NC
J Gastroenterol Hepatol; 2011 Feb; 26(2):213-5. PubMed ID: 21261708
[No Abstract] [Full Text] [Related]
2. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
3. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
[TBL] [Abstract][Full Text] [Related]
4. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
5. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
6. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809
[TBL] [Abstract][Full Text] [Related]
7. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
[TBL] [Abstract][Full Text] [Related]
8. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
Ray RM; Bhattacharya S; Johnson LR
Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
[TBL] [Abstract][Full Text] [Related]
9. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
[TBL] [Abstract][Full Text] [Related]
10. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
Peirce SK; Findley HW
Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis.
Cipriano R; Patton JT; Mayo LD; Jackson MW
Cell Cycle; 2010 Apr; 9(7):1373-9. PubMed ID: 20305378
[TBL] [Abstract][Full Text] [Related]
12. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.
Cheok CF; Kua N; Kaldis P; Lane DP
Cell Death Differ; 2010 Sep; 17(9):1486-500. PubMed ID: 20203688
[TBL] [Abstract][Full Text] [Related]
13. Syntaxin 6, a regulator of the protein trafficking machinery and a target of the p53 family, is required for cell adhesion and survival.
Zhang Y; Shu L; Chen X
J Biol Chem; 2008 Nov; 283(45):30689-98. PubMed ID: 18779328
[TBL] [Abstract][Full Text] [Related]
14. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
15. Studying p53 family proteins in yeast: induction of autophagic cell death and modulation by interactors and small molecules.
Leão M; Gomes S; Bessa C; Soares J; Raimundo L; Monti P; Fronza G; Pereira C; Saraiva L
Exp Cell Res; 2015 Jan; 330(1):164-77. PubMed ID: 25265062
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
17. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
18. Nutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cells.
Shi X; Liu J; Ren L; Mao N; Tan F; Ding N; Yang J; Li M
BMB Rep; 2014 Apr; 47(4):221-6. PubMed ID: 24286312
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
20. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]